^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MS4A1 mutation

    i
    Other names: MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, MS4A2, CD20, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5
    Entrez ID:
    931
    2years
    Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing. (PubMed, Br J Dermatol)
    In patients with MM that harbour a CD20+ subpopulation, combined therapy with BRAF inhibitor and anti-CD20 antibody could potentially kill residual MM cells and prevent disease recurrence.
    Journal
    |
    FOXM1 (Forkhead Box M1)
    |
    BRAF mutation • CD20 expression • MS4A1 mutation
    almost4years
    Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas. (ASCO 2022)
    In pts with R/R B-NHL treated with M, low BL CD20 expression is associated with lack of response to M. During M tx, loss of tumor cell expression of CD20 is one mechanism of acquired resistance; however, CD20 expression is maintained in most pts with PD, implying alternative mechanisms for acquired M resistance.
    Clinical
    |
    CD20 (Membrane Spanning 4-Domains A1) • PAX5 (Paired Box 5) • MS4A1 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression • MS4A1 mutation
    |
    Lunsumio (mosunetuzumab-axgb)
    over4years
    Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade. (PubMed, Clin Cancer Res)
    Our findings propose AXL as candidate factor of resistance to PD-1 blockade, and provide compelling support for screening both AXL and PD-L1 expression in the management of advanced ccRCC.
    Clinical • Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • AXL (AXL Receptor Tyrosine Kinase) • CD163 (CD163 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression • VHL mutation • AXL expression • MS4A1 mutation
    |
    Opdivo (nivolumab)